EG-009 is under clinical development by Shenzhen Evergreen Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome. According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EG-009 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EG-009 overview
EG-009 is under development for the prevention and treatment of Coronavirus disease 2019 (COVID-19) associated cytokine release syndrome. It is administered by oral route in the form of a soft capsule.
Shenzhen Evergreen Therapeutics overview
Shenzhen Evergreen Therapeutics is a pharmaceutical company focused on the research and development of innovative drugs in the fields of autoimmunity, ophthalmology, and chronic diseases. The company is headquartered in Shenzhen, Guangdong, China.
For a complete picture of EG-009’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.